Literature DB >> 3892742

Proliferative vitreoretinopathy and chemotherapeutic agents.

G A Peyman, J Schulman.   

Abstract

Proliferative vitreoretinopathy (PVR) is a disease process that occurs in eyes with rhegmatogenous retinal detachments and accounts for the majority of failures following retinal detachment surgery. PVR involves the uncontrolled proliferation of non-neoplastic cells capable of forming membranes, which may occur on either surface of the retina or along the detached surface of the vitreous gel. Contraction of these membranes creates tractional forces that can distort or detach the retina. Various surgical procedures have been used to repair retinal detachments associated with PVR. The results have not been encouraging in many instances. Recent efforts have been directed toward the chemical inhibition of cellular proliferation in PVR. The majority of drugs used in these studies have been antineoplastic agents that affect various phases in the cycle of cell growth.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3892742     DOI: 10.1016/0039-6257(85)90208-5

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  14 in total

1.  Cytotoxic effects of daunomycin on retinal pigment epithelium in vitro.

Authors:  M Weller; K Heimann; P Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1987       Impact factor: 3.117

2.  Real-time monitoring of sustained drug release using the optical properties of porous silicon photonic crystal particles.

Authors:  Elizabeth C Wu; Jennifer S Andrew; Lingyun Cheng; William R Freeman; Lindsey Pearson; Michael J Sailor
Journal:  Biomaterials       Date:  2010-11-30       Impact factor: 12.479

Review 3.  Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment.

Authors:  D G Charteris
Journal:  Br J Ophthalmol       Date:  1995-10       Impact factor: 4.638

Review 4.  Advances in the use of prodrugs for drug delivery to the eye.

Authors:  Pranjal Taskar; Akshaya Tatke; Soumyajit Majumdar
Journal:  Expert Opin Drug Deliv       Date:  2016-07-21       Impact factor: 6.648

5.  Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages.

Authors:  Y N Hui; H C Liang; Y S Cai; B Kirchhof; K Heimann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-02       Impact factor: 3.117

6.  Effects of selected repeated intravitreal chemotherapeutic agents.

Authors:  J Vernot; G A Peyman; R Gailitis; R Fiscella; M Woodhouse; D Weinberg
Journal:  Int Ophthalmol       Date:  1985-11       Impact factor: 2.031

7.  Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.

Authors:  Huiyuan Hou; Alejandra Nieto; Feiyan Ma; William R Freeman; Michael J Sailor; Lingyun Cheng
Journal:  J Control Release       Date:  2014-01-11       Impact factor: 9.776

8.  Liposome-encapsulated 3H-5FU in rabbits.

Authors:  P Fishman; G A Peyman; R Hendricks; S L Hui
Journal:  Int Ophthalmol       Date:  1989-09       Impact factor: 2.031

9.  Effect of postoperative subconjunctival 5-fluorouracil injections on the surgical outcome of trabeculectomy in the Japanese.

Authors:  Y Nakano; M Araie; S Shirato
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

10.  Evaluation of toxicity and efficacy of a combination of antineoplastic agents in the prevention of PVR.

Authors:  M Salah-Eldin; G A Peyman; M el-Aswad; B Bandok; M M Bahgat; M R Niesman
Journal:  Int Ophthalmol       Date:  1994       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.